-
EP4221738
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4221738
| EP4221738 - NUCLEIC ACID THERAPY FOR DIFFERENTIAL MODULATION OF HOST MICROFLORA [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 07.07.2023 Database last updated on 28.05.2024 | |
| Former | The international publication has been made Status updated on 08.04.2022 | ||
| Former | unknown Status updated on 19.11.2021 | Most recent event Tooltip | 01.12.2023 | Change: Validation states | published on 03.01.2024 [2024/01] | 01.12.2023 | Change - extension states | published on 03.01.2024 [2024/01] | Applicant(s) | For all designated states Alma Bio Therapeutics HQ Lyon Vaise Business Center 3, Place Giovanni Da Verrazzano 69009 Lyon / FR | [2023/32] | Inventor(s) | 01 /
BAUM, Binah 69009 Lyon / FR | 02 /
COHEN, Irun 69009 Lyon / FR | 03 /
MARGALIT, Raanan 69009 Lyon / FR | [2023/32] | Representative(s) | Straus, Alexander 2K Patent- und Rechtsanwälte - München Keltenring 9 82041 Oberhaching / DE | [2023/32] | Application number, filing date | 21802409.9 | 29.09.2021 | [2023/32] | WO2021IB58884 | Priority number, date | US202063085163P | 30.09.2020 Original published format: US 202063085163 P | [2023/32] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022070052 | Date: | 07.04.2022 | Language: | EN | [2022/14] | Type: | A1 Application with search report | No.: | EP4221738 | Date: | 09.08.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 07.04.2022 takes the place of the publication of the European patent application. | [2023/32] | Search report(s) | International search report - published on: | EP | 07.04.2022 | Classification | IPC: | A61K38/17, A61K48/00, A61P1/00, A61K35/00, A61K31/7088, A61K31/711 | [2023/32] | CPC: |
A61K38/1709 (EP,US);
A61K48/005 (EP,US);
A61K31/7088 (EP);
A61K31/711 (EP);
A61K45/06 (US);
A61P1/00 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/32] | Title | German: | NUKLEINSÄURETHERAPIE ZUR DIFFERENTIELLEN MODULATION DER WIRTSMIKROFLORA | [2023/32] | English: | NUCLEIC ACID THERAPY FOR DIFFERENTIAL MODULATION OF HOST MICROFLORA | [2023/32] | French: | THÉRAPIE PAR ACIDE NUCLÉIQUE POUR LA MODULATION DIFFÉRENTIELLE DE LA MICROFLORE HÔTE | [2023/32] | Entry into regional phase | 15.02.2023 | National basic fee paid | 15.02.2023 | Designation fee(s) paid | 15.02.2023 | Examination fee paid | Examination procedure | 28.07.2022 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 15.02.2023 | Amendment by applicant (claims and/or description) | 15.02.2023 | Examination requested [2023/32] | 15.02.2023 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 26.09.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO9834641 (UNIV FORDHAM [US]) [Y] 1-54 * page 17, line 8 - line 9 * * page 22, line 31 ** page 38, line 10 - line 14; claim 53 *; | [Y]US2001034042 (SRIVASTAVA PRAMOD K [US]) [Y] 1-54 * paragraphs [0096] , [0066]; claims 1,2,36 *; | [XY]KR100897778B (IUCF HYU [KR]) [X] 1,2,5,16-19,27 * paragraphs [0029] , [0 52] , [0 58] , [0 59] , [0 63] - [0 65]; claim 1 * [Y] 1-54; | [Y]US2014363397 (ALLEN-VERCOE EMMA [CA], et al) [Y] 1-54 * paragraphs [0010] , [0 13] , [0 14] , [0 17] - [0026] - [0 97] , [0 98] *; | [Y]US2016199424 (BERRY DAVID [US], et al) [Y] 1-54 * paragraphs [0022] - [0031]; example 1 *; | [XDY]WO2018178767 (ALMA BIO THERAPEUTICS [FR]) [XD] 1,2,16-19,27 * paragraphs [0005] - [ 13 ] - [0014] , [0 72] , [0089] * [Y] 1-54; | [Y]WO2020097483 (BRIGHAM & WOMENS HOSPITAL INC [US], et al) [Y] 1-54 * paragraphs [0033] , [ 34 ] , [ 35 ] , [ 36 ] , [ 153 ] , [ 304] * | by applicant | US6110744 | US6133029 | US6566128 | WO03096967 | US6669942 | US6794188 | WO2018178767 | - LITVAK et al., Current opinion in microbiology, (20170000), vol. 39, pages 1 - 6 | - MUKHOPADHYA et al., Nature reviews Gastroenterology & hepatology, (20120000), vol. 4, page 219 | - LIU et al., Arthritis Res Ther, (20200000), vol. 22, no. l, page 152 | - QUINTANA et al., Arthritis & Rheumatism, (20040000), vol. 50, pages 3712 - 3720 | - CHEN et al., BMC Genomics, (20060000), vol. 7, page 156 | - "NCBI", Database accession no. NP 001017963.2 | - MCCULLOUGH et al., Ther Deliv, (20120900), vol. 3, no. 9, pages 1077 - 99 |